Free Trial

hVIVO (LON:HVO) Shares Up 10% - What's Next?

hVIVO logo with Medical background

hVIVO plc (LON:HVO - Get Free Report)'s share price rose 10% during mid-day trading on Monday . The stock traded as high as GBX 22 ($0.27) and last traded at GBX 21.25 ($0.26). Approximately 7,804,669 shares changed hands during mid-day trading, an increase of 164% from the average daily volume of 2,961,263 shares. The stock had previously closed at GBX 19.33 ($0.24).

hVIVO Price Performance

The company has a market capitalization of £144.58 million, a PE ratio of 708.33 and a beta of 0.97. The stock's 50-day moving average is GBX 20.36 and its two-hundred day moving average is GBX 25.73. The company has a current ratio of 1.61, a quick ratio of 1.16 and a debt-to-equity ratio of 33.86.

About hVIVO

(Get Free Report)

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in hVIVO Right Now?

Before you consider hVIVO, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and hVIVO wasn't on the list.

While hVIVO currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

NVIDIA Stock Under Pressure: DeepSeek and the AI Tech War

NVIDIA Stock Under Pressure: DeepSeek and the AI Tech War

NVIDIA's stock took a historic plunge, falling 17% on news of China's DeepSeek AI model; is now the time to buy the dip or wait for more volatility ahead?

Related Videos

Pelosi Bets Big on AI: Her Top 5 Stock Picks
7 Stocks to Benefit From Trump’s Tariffs in 2025
7 Large-Cap Stocks Headed for Strong, Steady Gains in 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines